GlyceroPhosphoCholine

IMPROVED GlyceroPhosphoCholine is now available!

To better reflect the dosages that were used in most clinical studies (600-1200 mg per day), GlyceroPhosphoCholine (GPC) has been reformulated to a 300 mg per capsule dosage, and is now available in a 60 count size (which yields 33% more GPC per bottle than the previous GPC product).

GPC (GlyceroPhosphoCholine) is a protective orthomolecular nutri­ent for the brain, kidneys, muscles, testes and other organs, and a water-phase building block for cell membrane phospholipids. GPC is proven through randomized controlled trials as highly effective for brain circulatory insufficiency and recovery from ischemic damage or other trauma.

When used at the higher therapeutic ranges of 600-1200 mg per day, this will be a 15-30 day supply. The maintenance dosage with GPC is 300-600 mg per day, which translates to a 30-60 day supply.

L-Alpha Glycero Phospho Choline (GPC) is a naturally occurring phospholipid precurser and metabolite derived from soy lecithin. GPC is a nutrient that safely and naturally sharpens alertness, concentration and other cognitive functions. GPC has been shown to promote the effects of growth hormone releasing hormone and increase human growth hormone (hGH) secretion in both young and elderly individuals as well as patients with Senile Dementia similar to Alzheimer’s disease. GPC also affects numerous biochemical and neurotrasmitter systems that have been involved in the development of age-related memory dysfunction.

• Memory
• Cognitive Function
• Recovery Time In Head Injury Patients
• Attention Span
• Mental and Physical Performance in Healthy Individuals
• Strength and Endurance during Workouts
• Liver and Brain Function
• Coordination
• Human Growth Hormone Secretion

Serving Size:
1 capsule
Servings per container 60

Product Contains:

• Glycerophosphocholine 300 mg

Other Ingredients: Microcrystalline cellulose, dicalcium phosphate, silicon dioxide, magnesium stearate.

Recommended Use: As a dietary supplement, take one or more capsules daily or as directed by your health care practitioner.

Click Here to read Dr. Parris Kidd's research summary on the benefits of GPC for brain health

Read Customer questions and answers about Brain Wellness in our FAQ.

Intensive Brain Support

GPC (also known in the research literature as L-alpha-glycerylphosphorylcholine or choline alfoscerate) is a naturally occurring molecule in all the body's cells and mother's milk. GPC is an "activated" form of choline, the difference stemming from the addition of a phosphate and glycerol group.

Unlike Phosphatidyl Choline, GPC is water soluble, it crosses the blood brain barrier, and it requires less energy on the pathway to acetylcholine synthesis or addition of specific brain fatty acids such as DHA. [1]

In humans, GPC taken by mouth is well absorbed and increases plasma levels of choline for up to ten hours. Research with animals using radio labeled GPC suggests GPC becomes incorporated into many other regulatory and structural molecules with various functions:

a methyl group source for gene-level and other metabolic control

as a precursor to acetylcholine, which is used in the brain as a neurotransmitter
and the rest of the body as a messenger/regulator (muscle contraction, organ
function, skin tone, blood vessel volume, platelet aggregation)

for incorporation into choline phospholipids such as phosphatidyl choline and
sphingomyelin in every cell membrane and myelin sheath.

At least twenty-three clinical trials have been done with GPC, all of them with positive outcomes. [23]

improvements in attention, mental focus, recall, and other higher mental
functions (cognition), including in young healthy subjects, [3,4] whether linked to
poor brain circulation or of the Alzheimer's type [5]

brain recovery following stroke or other circulatory injury [6-8]

revitalizes master hormone functions from pituitary control (such as Growth
Hormone) in the elderly [9]
The typical oral doses of GPC used in most trials were 1200 mg per day in divided doses, in order to maintain the plasma levels at a high level throughout 24 hrs.

GPC (GlyceroPhosphoCholine) ® Research shows that GPC can improve:

Memory/mental focus function in elderly and young

Mood status

Growth Hormone production

Brain recovery from stroke or injury or anesthesia

Age-related changes in brain function

Impairment in cognition and social behavior due to Alzheimer's or vascular dementia

Phos. Choline vs. GPC
Compared with other dietary "cholinergic precursors" such as choline, phosphatidyl choline or (citicholine), GPC had superior benefits. [17]

GPC outperformed the nutraceutical citicholine (cytidine diphosphocholine or CDP Choline) in three direct comparison trials. [18-20]

In comparison with prescription drugs GPC showed to be:

better than Oxiracetam. [21]

similar to the Donezepil and superior to Rivastigmine, both of which are acetylcholinesterase inhibitor drugs. [33]

In all the trials GPC improved overall clinical symptoms such as:

cognition, affective symptoms, and somatic symptoms such as fatigue and dizziness

Memory, attention, other cognitive measures, and mood

disorientation, irritability, emotional stability, and indifference to surroundings

In a study of advanced Alzheimer's patients, GPC performed roughly twice as well as acetyl-L-carnitine. [25]

The largest stroke trial used 176 hospital centers within Italy and 2,044 patients, and showed that GPC significantly helped more than 95 percent of the patients. [7]

GPC supports other neurotransmitter systems such as dopamine, norepinephrine, and GABA41, improves EEG (ElectroEncephaloGraphic) patterns, and reduces the delta or "slow waves" which are increased during aging or accelerated cognitive deterioration. [43]

Store In A Cool, Dry Place. Keep Out Of Reach Of Children.

This product does not contain wheat, yeast, eggs, dairy, corn, animal products, artificial colors, flavors and preservatives.

Click here to download GPC PDF file

1. Kidd P, GPC (GlyceroPhosphoCholine),Ortho-Nutraceutical For Active Living and HealthyAging. Townsend Letters…Soon To Be Published
3. Canal N, et al. Effect of l-alpha-glyceryl-phosphorylcholine on amnesia caused by scopolamine. International J Clin Pharmacol Therapy Toxicol 1991;29:103.
4. Canal N, et al. Comparison of the effects of pretreatment with choline alfoscerate, idebenone, aniracetam and placebo on scopolamine-induced amnesia. Le Basi Raz Ter 1993;23:102.
5. Parnetti L, Amenta F, Gallai V. Choline alfoscerate in cognitive decline and in acutecerebrovascular disease: an analysis of published clinical data. Mechs Ageing Dev2001;22:2041.
6. Aguglia E, et al. Choline alphoscerate in the treatment of mental pathology following acute cerebrovascular accident. Funct Neurol 1993;8 (Suppl):5.
7. Barbagallo Sangiorgi G, et al. alpha-glycerophosphocholine in the mental recovery of cerebral ischemic attacks. Ann N Y Acad Sci 1994;717:253.
8. Tomasina C, et al. Clinical study of the therapeutic effectiveness and tolerability of choline alfoscerate in 15 subjects with compromised cognitive functions subsequent to acute focal cerebral ischemia. Rivista Neuropsi Sci Affini 1996;37:21.
9. Ceda GP, et al. Effects of an acetylcholine precursor on GH secretion in elderly subjects. In: Bercu, BB, Walker, RF, eds. Growth Hormone II: Basic and Clinical Aspects.Springer- Verlag;1994.
17. Amenta F, et al. Treatment of cognitive dysfunction associated with Alzheimer's disease with cholinergic precursors. Ineffective treatments or inappropriate approaches? Mechs Ageing Dev 2001;122:2025.
18. Di Perri R, et al. A multicentre trial to evaluate the efficacy and tolerability of alphaglycerylphosphorylcholine versus cytosine diphosphocholine in patients with vascular dementia. J Intl Med Res 1991;19:330.
19. Frattola L, et al. Multicenter clinical comparison of the effects of choline alfoscerate and cytidine diphosphocholine in the treatment of multi-infarct dementia. Curr Therap Res 1991;49:683.
20. Muratorio A, et al. A neurotropic approach to the treatment of multi-infarct dementia using Lalpha-glycerylphosphorylcholine. Curr Ther Res 1992;52:741.
21. Paciaroni E, Tomassini PF. Clinical study of effectiveness and tolerability of alpha-GFC (choline alfoscerate) vs. oxiracetam in patients suffering from slight/moderate cognitive defect of vascular origin. Gior Ital Rech Clin Terap 1993;14:29.
22. Ban TA, et al. Choline alfoscerate in elderly patients with cognitive decline due to dementing illness. New Trends Clin Neuropharmacol 1991;5:87.
23. Palleschi M, et al. Evaluation of effectiveness and tolerability of alpha-GFC (choline alfoscerate) in patients suffering from slight/moderate cognitive decline. Preliminary results.Geriatria 1992;4:13.
25. Parnetti L, et al. Multicentre study of l-a-glyceryl-phosphorylcholine vs ST200 among patients with probable senile dementia of Alzheimer's type. Drugs & Aging 1993;3:159.
33. Wirthenson G, et al. Role and regulation of glycerophosphocholine in rat renal papilla. Pflu(e)gers Arch. 1987;409:411.
41. Ferraro L, Tanganelli S, Marani L, et al. Evidence for an in vivo and in vitro modulation of endogenous cortical GABA release by alpha-glycerylphosphorylcholine. Neurochem Res 1996;21:547.
42. Schettini G, et al. Molecular mechanisms mediating the effects of l-alphaglycerylphosphorylcholine, a new cognition-enhancing drug, on behavioral and biochemical parameters in young and aged rats. Pharmacol Biochem Behavior 1992;43:139.
43. Lacomba C, et al. Effects of l-alpha-glycerylphosphorylcholine on the EEG power spectrum in the rat. Drug Dev Res 1992;26:101.
44. Infante JP. Defective synthesis of polyunsaturated phosphatidylcholines as the primary lesion in Duchenne and murine dy muscular dystrophies. Med Hypoth 1986;19:113.